Our results also demonstrated that the combination of anti-TNFR2 mAb and anti-PD1 mAb had better therapeutic efficacy than either antibody alone in both anti-PD1-responsive and anti-PD1-unresponsive CRC mouse models. This evidence concerns the gene TNFRSF1B and colorectal carcinoma.